Integra LifeSciences to Acquire Acclarent for ~$280M
Shots:
- Integra LifeSciences has entered into a definitive agreement to acquire Acclarent from Ethicon, an integral part of Johnson & Johnson MedTech company, for $275M in cash (subject to customary purchase price adjustments) in addition to $5M regulatory milestones. The transaction is expected to close by Q2’24
- Integra expects to enhance its global presence in the ENT market by acquiring Acclarent for its expertise in ENT devices with a portfolio comprising many ENT products & technologies. The collaboration also expects to potentiate collaborations between ENT & neurosurgeons
- Acclarent ENT portfolio comprises balloon technologies for sinus dilation and eustachian tube dilation along with surgical navigation systems
Ref: GE HealthCare | Image: GE HealthCare
Related News:- GE HealthCare and AirStrip Signs a Joint Commercialization Agreement for Integrated Patient Monitoring and Cardiac Data Visualization
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
